Short-chain fatty acids and gut microbiota in multiple sclerosis.
Pernille MelbyeAnna OlssonTue H HansenHelle B SøndergaardAnnette Bang OturaiPublished in: Acta neurologica Scandinavica (2018)
Studies of EAE in mice suggest that SCFAs may play a role in the development and progression of EAE, but so far this has not been confirmed in humans. An aberrant gut microbiota in MS patients has been reported to be differentially abundant compared with healthy controls, although with little consistency in the bacterial taxa. Further investigations are required to elucidate the involvement of the gut microbiota and its metabolites, including potential beneficial effects of SCFAs, in the development and course of MS.